Kiwi, No. You miss my point. The presence of a generic option has created a problem in the US market. It is a problem that Amarin doesn't have the financial resources to address. Not at the moment. The size of the population that would benefit from Vascepa is unchanged. Assuming that the issue is as KM explained, do you believe that this group of patients will never be treated? Do you share the opinion of Dr. Steve? Do you think that Vascepa has no medical value? If that is your opinion then investing in Amarin would be a mistake. If you believe in the accuracy of the clinical trials, this is a sound investment. The estimate of the US treatable population is not mine. I do agree with it. In time doctors will proscribe the drug. Unless your doctor is ralphey.
Sleven,
News 
Market Data 
Discover 
